This infection occurred in a patient who had a CD4+-T-cell count only slightly above 200/μl before the beginning of therapy, but who had subsequently fallen below 200/μl during therapy and had not received anti-zoster-prophylaxis in between. This evidence concerns the gene CD4 and infection.